Abstract 542 Table 1
OVARIAN CANCER
SourceStudyTotal_RecruitedTumor_contentViabilityFormulations_testedRandomisationBlindingHGSOC_recruitedHGSOC-ctx-naiveSuccess_rateHGSOC_ORG_LINESnon-HGSOC_Donorsnon-HGSOC_Donors_ctxnaiveORG_LinesBOT_DonorsBOT_Successful_lines
Suppl table 4 Kopper 2019 49 45% N/A 3 formulations N/A N/A 13 2 0.55 26 12 9 22 8 7
Suppl table 1 de Witte 2020 7 34% N/A 2 formulations N/A N/A 4 0 N/A 3 1 1 5 N/A N/A
Table 1 Maenhoudt 2020 27 N/A N/A 4 formulations N/A N/A 22 4 0.66 26 5 4 5 N/A N/A
Table EV1 Hoffmann 2020 45 N/A N/A 6 formulations N/A N/A 13 N/A 0.30 13 N/A N/A N/A N/A N/A
Table 2 Nanki 2020 35 N/A N/A 20 formulations N/A N/A 10 N/A 0.90 9 15 N/A 13 3 3
Table 1 Maru 2019 15 N/A N/A 2 formulations N/A N/A 4 4 0.75 3 5 5 3 6 3
Figure 1B Hill 2018 N/A N/A N/A 1 formulation N/A N/A 21 9 1.00 32 2 1 0 N/A N/A
Total 178 40% 87 19 0.71 112 40 20 48 17 13
0.22 0.50
UTERINE CANCER
Total_Recruited Tumor_content Viability Formulations_tested Randomisation Blinding Success_rate G1 endometrioid G2 endometrioid G3 endometrioid serous Other Lynch_syndrom MOLECULAR_CLASSES
Suppl Table 1 Boretto 2019 16 N/A N/A 2 formulations N/A N/A 0.42 8 3 0 3 2 1 N/A
Suppl Table 1 Turco 2017 3 N/A N/A 1 formulation N/A N/A N/A 1 1 0 1 N/A N/A N/A
Table 1 Girda 2017 15 N/A N/A 1 formulation N/A N/A N/A 7 3 5 0 N/A N/A N/A
Table 1 Maru 2019 6 N/A N/A 2 formulations N/A N/A 0.83 2 2 1 0 1 N/A N/A
Total 40 0.63 18 9 6 4 3 1 N/A
CERVICAL CANCER
Total_Recruited Tumor_content Viability Formulations_tested Randomisation Blinding SCC Organoid_outgrowth Efficiency AdenoCa Organoid_outgrowth Efficiency
Table S1 Lõhmussaar 2021 26 N/A N/A 7 formulations + withdrawal test N/A N/A 22 11 0.50 4 1 0.25